STOCK TITAN

Kintara Therapeutics Inc - KTRA STOCK NEWS

Welcome to our dedicated news page for Kintara Therapeutics (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kintara Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kintara Therapeutics's position in the market.

Rhea-AI Summary
Kintara Therapeutics, Inc. announced financial results for Q2 2023, including a net loss of $1.0 million. They initiated a study for cutaneous metastatic breast cancer and terminated the development of VAL-083. The company aims to maximize shareholder value through strategic alternatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
earnings
-
Rhea-AI Summary
Kintara Therapeutics (KTRA) initiates a 15-patient clinical trial for REM-001 in cutaneous metastatic breast cancer, supported by a $2.0 million NIH grant. The trial aims to confirm the planned dose and study design for a Phase 3 trial, with promising efficacy data and FDA Fast Track Designation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
clinical trial
-
Rhea-AI Summary
Kintara Therapeutics, Inc. (Nasdaq: KTRA) has initiated a strategic review process to maximize stockholder value and has engaged Ladenburg Thalmann & Co. Inc. as its financial advisor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.81%
Tags
none
Rhea-AI Summary
Kintara Therapeutics, Inc. (Nasdaq: KTRA) has received an extension until March 18, 2024, to regain compliance with Nasdaq's Listing Rule 5550(b). Failure to comply may lead to potential delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.66%
Tags
none
-
Rhea-AI Summary
Kintara Therapeutics, Inc. (KTRA) Announces Q1 Financial Results and Corporate Update, Focuses on REM-001 Program and Receives $2M NIH Grant for CMBC Treatment. Preliminary topline results from GBM AGILE study led to the suspension of VAL-083 development. Kintara aims to maximize shareholder value through strategic options. Financially, the company had $0.2M cash and reported a net loss of $3.0M for Q1 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
earnings
-
Rhea-AI Summary
Kintara Therapeutics announced that the preliminary results from the GBM AGILE study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. As a result, the company is suspending the development of VAL-083 and shifting its focus to the REM-001 program. Kintara will also explore strategic opportunities to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-79.68%
Tags
clinical trial
Rhea-AI Summary
Kintara Therapeutics to present at Dawson James Small Cap Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.81%
Tags
conferences
-
Rhea-AI Summary
Kintara Therapeutics' President and CEO will present at LD Micro Main Event XVI Conference on October 4, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.08%
Tags
conferences
-
Rhea-AI Summary
Kintara Therapeutics presents patient case studies at EANO Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
none
Rhea-AI Summary
Kintara Therapeutics announces financial results for FY2023, with a net loss of $14.6M compared to $22.7M in FY2022. Cash and cash equivalents as of June 30, 2023, were approximately $1.5M. The company received a $2.0M SBIR grant from NIH for the development of REM-001. Kintara will present data on its lead program, VAL-083, at the EANO Annual Meeting. CEO anticipates announcing top-line data in the international registrational GBM AGILE Study by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.97%
Tags
earnings
Kintara Therapeutics Inc

Nasdaq:KTRA

KTRA Rankings

KTRA Stock Data

3.83M
39.03M
0.21%
0.62%
4.84%
Polish and Other Sanitation Good Manufacturing
Manufacturing
Link
US
San Diego